company background image
HAML

Hamlet Pharma NGM:HAMLET B Stock Report

Last Price

kr4.09

Market Cap

kr444.8m

7D

6.9%

1Y

-39.9%

Updated

15 Aug, 2022

Data

Company Financials
HAMLET B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

HAMLET B Stock Overview

Hamlet Pharma AB (publ), a pharmaceutical company, engages in the research and development of cancer drugs.

Hamlet Pharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hamlet Pharma
Historical stock prices
Current Share Pricekr4.09
52 Week Highkr7.45
52 Week Lowkr3.01
Beta0.74
1 Month Change9.50%
3 Month Change0.99%
1 Year Change-39.85%
3 Year Change-70.07%
5 Year Change14.67%
Change since IPO75.29%

Recent News & Updates

Jun 17
We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

HAMLET BSE BiotechsSE Market
7D6.9%0.7%0.9%
1Y-39.9%-20.3%-20.9%

Return vs Industry: HAMLET B underperformed the Swedish Biotechs industry which returned -20.6% over the past year.

Return vs Market: HAMLET B underperformed the Swedish Market which returned -21.8% over the past year.

Price Volatility

Is HAMLET B's price volatile compared to industry and market?
HAMLET B volatility
HAMLET B Average Weekly Movement7.6%
Biotechs Industry Average Movement8.9%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market4.5%

Stable Share Price: HAMLET B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: HAMLET B's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a5Martin Erixonhttps://www.hamletpharma.com

Hamlet Pharma AB (publ), a pharmaceutical company, engages in the research and development of cancer drugs. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company is based in Lund, Sweden.

Hamlet Pharma AB (publ) Fundamentals Summary

How do Hamlet Pharma's earnings and revenue compare to its market cap?
HAMLET B fundamental statistics
Market Capkr444.83m
Earnings (TTM)-kr10.05m
Revenue (TTM)kr13.02m

34.2x

P/S Ratio

-44.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HAMLET B income statement (TTM)
Revenuekr13.02m
Cost of Revenuekr0
Gross Profitkr13.02m
Other Expenseskr23.07m
Earnings-kr10.05m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 26, 2022

Earnings per share (EPS)-0.092
Gross Margin100.00%
Net Profit Margin-77.18%
Debt/Equity Ratio0.0%

How did HAMLET B perform over the long term?

See historical performance and comparison